Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasotraline in adults with moderate to severe Binge Eating Disorder
NCT02564588Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing Dasotraline with Placebo (2 arms). Primary endpoint: Change from baseline in number of binge days per week at 12 weeks. Started Oct 2015; status: completed.
02
Drugs
dasotraline
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT02564588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564588.